| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H14N2 |
| Molar mass | 198.269 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lanicemine (AZD6765) is a low-trappingNMDA receptor antagonist that was underdevelopment byAstraZeneca for the management of severe andtreatment-resistant depression.[1][2] Lanicemine differs fromketamine in that it is alow-trappingNMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]